Stockreport

Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]

ACADIA Pharmaceuticals Inc.  (ACAD) 
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF NUPLAZID's patent protection now extends to 2030, supporting 10% Y/Y revenue growth and providing a stable revenue base. DAYBUE missed launch expectations but remains [Read more]